Laden...
Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH). Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 01/27/2022 06:30 PM ESTNIH trial compared hIVIG plus remdesivir to remdesivir alone.
|
Laden...
Laden...